UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

European heart journal, 2022-10, Vol.43 (38), p.3618-3731

2022

Volltextzugriff (PDF)

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)

European heart journal, 2016-01, Vol.37 (1), p.67-119

2016

Volltextzugriff (PDF)

Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018

International journal of cardiology, 2018-12, Vol.272, p.37-45

2018

Volltextzugriff (PDF)

Gezielte Therapie der pulmonal arteriellen Hypertonie: Empfehlungen der Kölner Konsensuskonferenz 2016

Deutsche medizinische Wochenschrift, 2016-10, Vol.141 (S 01), p.S33-S41

2016

Volltextzugriff (PDF)

Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist

Biochemical pharmacology, 2012-07, Vol.84 (1), p.68-75

2012

Volltextzugriff (PDF)

Comparison of inhaled nitric oxide with aerosolized prostacyclin or analogues for the postoperative management of pulmonary hypertension: a systematic review and meta-analysis

Annals of medicine (Helsinki), 2020-05, Vol.52 (3-4), p.120-130

2020

Volltextzugriff (PDF)

Inhalation of repurposed drugs to treat pulmonary hypertension

Advanced drug delivery reviews, 2018-08, Vol.133, p.34-44

Gessler, Tobias

2018

Volltextzugriff (PDF)

Prostacyclin analogues decrease platelet aggregation but have no effect on thrombin generation, fibrin clot structure, and fibrinolysis in pulmonary arterial hypertension: PAPAYA coagulation

Platelets (Edinburgh), 2022-10, Vol.33 (7), p.1065-1074

2022

Volltextzugriff (PDF)

Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Controlled Trial

Circulation (New York, N.Y.), 2013-02, Vol.127 (5), p.624-633

2013

Volltextzugriff (PDF)

The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension

Basic & clinical pharmacology & toxicology, 2020-01, Vol.126 (1), p.32-42

2020

Volltextzugriff (PDF)

The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors

Prostaglandins & other lipid mediators, 2015-07, Vol.120, p.56-71

2015

Volltextzugriff (PDF)

Smooth Muscle Proliferation and Role of the Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial Hypertension

American journal of respiratory and critical care medicine, 2010-11, Vol.182 (9), p.1161-1170

2010

Volltextzugriff (PDF)

A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension

Current pharmaceutical design, 2017-01, Vol.23 (34)

2017

Volltextzugriff (PDF)

Treprostinil treatment decreases circulating platelet microvesicles and their procoagulant activity in pediatric pulmonary hypertension

Pediatric pulmonology, 2019-01, Vol.54 (1), p.66-72

2019

Volltextzugriff (PDF)

Early Use of Iloprost in Nonfreezing Cold Injury

Wilderness & environmental medicine, 2022-09, Vol.33 (3), p.344-347

2022

Volltextzugriff (PDF)

Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil

The European respiratory journal, 2006-12, Vol.28 (6), p.1195-1203

2006

Volltextzugriff (PDF)

Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension

Journal of clinical medicine, 2021-03, Vol.10 (5), p.1024

2021

Volltextzugriff (PDF)

Antiplatelet effects of prostacyclin analogues: Which one to choose in case of thrombosis or bleeding?

Cardiology journal, 2021, Vol.28 (6), p.954-961

2021

Volltextzugriff (PDF)

Short term effect of intravenous treprostinil in term and preterm infants with pulmonary hypertension

BMC pediatrics, 2024-01, Vol.24 (1), p.83-83, Article 83

2024

Volltextzugriff (PDF)

IP receptor-dependent activation of PPARγ by stable prostacyclin analogues

Biochemical and biophysical research communications, 2007-09, Vol.360 (4), p.821-827

2007

Volltextzugriff (PDF)

Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells

Thrombosis and haemostasis, 2015-10, Vol.114 (4), p.735-747

2015

Volltextzugriff (PDF)

Immune Modulation to Enhance Bone Healing-A New Concept to Induce Bone Using Prostacyclin to Locally Modulate Immunity

Frontiers in immunology, 2019-04, Vol.10, p.713-713

2019

Volltextzugriff (PDF)

Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series

European heart journal : case reports, 2020-12, Vol.4 (6), p.1-7

2020

Volltextzugriff (PDF)

Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension . A Double-blind, Randomized, Placebo-controlled Trial

American journal of respiratory and critical care medicine, 2002-03, Vol.165 (6), p.800-804

2002

Volltextzugriff (PDF)

Case report: Stepwise transition from subcutaneous treprostinil to epoprostenol in high-risk pulmonary arterial hypertension

European heart journal : case reports, 2021-10, Vol.5 (10), p.ytaa578

2021

Volltextzugriff (PDF)

1 – 25 von 773

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(717)
Mit Volltextzugriff
(649)

Publikationsform

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(619)
Life Sciences & Biomedicine
(604)
Prostacyclin
(516)
Animals
(389)
Humans
(370)
Male
(359)
Epoprostenol - Analogs & Derivatives
(329)
Biological And Medical Sciences
(315)
Medical Sciences
(225)
Epoprostenol - Pharmacology
(215)
Female
(212)
Pharmacology & Pharmacy
(190)
Cardiovascular System & Cardiology
(184)
Rats
(176)
Pharmacology. Drug Treatments
(138)
Cardiac & Cardiovascular Systems
(123)
Adult
(113)
Epoprostenol - Therapeutic Use
(111)
Middle Aged
(111)
Pulmonary Hypertension
(111)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018

Gezielte Therapie der pulmonal arteriellen Hypertonie: Empfehlungen der Kölner Konsensuskonferenz 2016

Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist

Comparison of inhaled nitric oxide with aerosolized prostacyclin or analogues for the postoperative management of pulmonary hypertension: a systematic review and meta-analysis

Inhalation of repurposed drugs to treat pulmonary hypertension

Prostacyclin analogues decrease platelet aggregation but have no effect on thrombin generation, fibrin clot structure, and fibrinolysis in pulmonary arterial hypertension: PAPAYA coagulation

Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Controlled Trial

The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension

The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors

Smooth Muscle Proliferation and Role of the Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial Hypertension

A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension

Treprostinil treatment decreases circulating platelet microvesicles and their procoagulant activity in pediatric pulmonary hypertension

Early Use of Iloprost in Nonfreezing Cold Injury

Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil

Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension

Antiplatelet effects of prostacyclin analogues: Which one to choose in case of thrombosis or bleeding?

Short term effect of intravenous treprostinil in term and preterm infants with pulmonary hypertension

IP receptor-dependent activation of PPARγ by stable prostacyclin analogues

Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells

Immune Modulation to Enhance Bone Healing-A New Concept to Induce Bone Using Prostacyclin to Locally Modulate Immunity

Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series

Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension . A Double-blind, Randomized, Placebo-controlled Trial

Case report: Stepwise transition from subcutaneous treprostinil to epoprostenol in high-risk pulmonary arterial hypertension

Suchergebnisse filtern